{"protocolSection": {"identificationModule": {"nctId": "NCT00736489", "orgStudyIdInfo": {"id": "D0570C00007"}, "secondaryIdInfos": [{"id": "ToBe"}], "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "Single-dose Crossover Study to Investigate Pharmacodynamics of AZD3199", "officialTitle": "A Phase II, Double-blind, Placebo-controlled, Randomised, 6-way Cross-over, Single-dose Study to Investigate the Local and Systemic Effects of 3 Doses of Inhaled AZD3199 (a \u03b22-agonist) Compared to Formoterol in Asthmatic Patients"}, "statusModule": {"statusVerifiedDate": "2014-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-08"}, "primaryCompletionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-08-15", "studyFirstSubmitQcDate": "2008-08-15", "studyFirstPostDateStruct": {"date": "2008-08-18", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-11-30", "resultsFirstSubmitQcDate": "2014-02-21", "resultsFirstPostDateStruct": {"date": "2014-04-03", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-05-08", "lastUpdatePostDateStruct": {"date": "2014-05-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate the pharmacodynamics of single doses of AZD3199 in asthmatic patients."}, "conditionsModule": {"conditions": ["Asthma", "Airway Obstruction"], "keywords": ["Asthma", "airway obstruction", "beta2-agonist", "efficacy", "inhalation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 37, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "crossover dose 1", "type": "EXPERIMENTAL", "description": "AZD3199 120 microgram", "interventionNames": ["Drug: AZD3199"]}, {"label": "crossover dose 2", "type": "EXPERIMENTAL", "description": "AZD3199 480 microgram", "interventionNames": ["Drug: AZD3199"]}, {"label": "crossover dose 3", "type": "EXPERIMENTAL", "description": "AZD3199 1920 microgram", "interventionNames": ["Drug: AZD3199"]}, {"label": "crossover dose 4", "type": "PLACEBO_COMPARATOR", "description": "Placebo", "interventionNames": ["Drug: Placebo"]}, {"label": "crossover dose 5", "type": "ACTIVE_COMPARATOR", "description": "Formoterol 9 microgram", "interventionNames": ["Drug: Formoterol"]}, {"label": "crossover dose 6", "type": "ACTIVE_COMPARATOR", "description": "Formoterol 36 microgram", "interventionNames": ["Drug: Formoterol"]}], "interventions": [{"type": "DRUG", "name": "AZD3199", "description": "Dry powder for inhalation, single dose", "armGroupLabels": ["crossover dose 1", "crossover dose 2", "crossover dose 3"]}, {"type": "DRUG", "name": "Formoterol", "description": "Dry powder for inhalation, single dose", "armGroupLabels": ["crossover dose 5", "crossover dose 6"], "otherNames": ["Oxis"]}, {"type": "DRUG", "name": "Placebo", "description": "Dry powder for inhalation, single dose", "armGroupLabels": ["crossover dose 4"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "FEV1 Peak Effect Within 0 - 24 h Post-dose", "description": "Maximum FEV1 value", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h"}, {"measure": "E22-26: the Average of the FEV1 Value Between 22 and 26 h Post Dose for Every Treatment Visit.", "description": "Residual FEV1 24 h post-dose", "timeFrame": "22- 26 h post dose"}, {"measure": "S-potassium, Peak Effect Over 0 - 4 h Post-dose", "description": "Minimum S-potassium concentration (A well-known effect of beta2-agonists (AZD3199 is a beta2-agonist) is a reduction in serum potassium levels. The minimum value has therefore been evaluated.", "timeFrame": "0, 15min, 30min,1h, 2h, 4h"}, {"measure": "S-potassium, Average Effect Over 0 - 4 h Post-dose", "description": "Average S-potassium concentration", "timeFrame": "0, 15min, 30min,1h, 2h, 4h"}], "secondaryOutcomes": [{"measure": "FEV1 Effect at 5 Min Post-dose", "description": "FEV1 at 5 minutes", "timeFrame": "5min"}, {"measure": "FEV1 Average Effect Over 0 - 24 h Post-dose", "description": "FEV1 average effect over 24 h dosing interval", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h"}, {"measure": "FEV1 Average Effect Over 0 - 12 h Post-dose", "description": "FEV1 average effect over 12 h day-time period", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h"}, {"measure": "FEV1 Average Effect Over 12 - 24 h Post-dose", "description": "FEV1 average effect over 12 h night-time period", "timeFrame": "12h, 14h, 18h, 22h, 24h"}, {"measure": "Systolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum SBP value over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Systolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose", "description": "Average SBP value over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Diastolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose", "description": "Minimum DBP value over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Diastolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose", "description": "Average DBP value over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Pulse, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum pulse over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Pulse, Average Effect Over 0 - 4 h Post-dose", "description": "Average pulse over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Heart Rate, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum heart rate over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Heart Rate, Average Effect Over 0 - 4 h Post-dose", "description": "Average heart rate over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "QTcB, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum QTc Bazett over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "QTcB, Average Effect Over 0 - 4 h Post-dose", "description": "Average QTc Bazett over 4 h", "timeFrame": "0, 30min, 2h, 4h"}, {"measure": "Tremor, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h"}, {"measure": "Tremor, Average Effect Over 0 - 4 h Post-dose", "description": "Average tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h"}, {"measure": "Palpitations, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h"}, {"measure": "Palpitations, Average Effect Over 0 - 4 h Post-dose", "description": "Average palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h"}, {"measure": "Plasma AZD3199 Cmax", "description": "Maximum plasma concentration of AZD3199 measured", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h"}, {"measure": "Plasma AZD3199 AUC0-24", "description": "Area under the plasma concentration curve from time 0 to 24 h post-dose", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Asthmatic patients with pre-bronchodilatory FEV1 above 60% of predicted normal and above 1.5 liters.\n* Men and post-menopausal women above 18 years of age.\n* Reversible airway obstruction in response to classical beta2-agonist (salbutamol)\n* Non/ex-smokers\n\nExclusion Criteria:\n\n* Any clinically significant disease or disorder other than asthma\n* Any clinically relevant abnormal findings at screening examinations\n* Treatment with systemic glucocorticosteroids within the past 30 days\n* Inhaled corticosteroid use if dosing is not kept constant", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Prof Leif Bjermer, MD, PhD", "affiliation": "University Hospital in Lund, Sweden", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Research Site", "city": "Hvidovre", "country": "Denmark", "geoPoint": {"lat": 55.65719, "lon": 12.47364}}, {"facility": "Research Site", "city": "Gothenburg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"facility": "Research Site", "city": "Lulea", "country": "Sweden", "geoPoint": {"lat": 65.58415, "lon": 22.15465}}, {"facility": "Research Site", "city": "Lund", "country": "Sweden", "geoPoint": {"lat": 55.70584, "lon": 13.19321}}]}, "referencesModule": {"references": [{"pmid": "23907810", "type": "DERIVED", "citation": "Bjermer L, Rosenborg J, Bengtsson T, Lotvall J. Comparison of the bronchodilator and systemic effects of AZD3199, an inhaled ultra-long-acting beta(2)-adrenoceptor agonist, with formoterol in patients with asthma. Ther Adv Respir Dis. 2013 Oct;7(5):264-71. doi: 10.1177/1753465813497527. Epub 2013 Aug 1."}], "seeAlsoLinks": [{"label": "Related Info", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=238&filename=CSR-D0570C00007.pdf"}, {"label": "D0570C00007 CSR Synopsis", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=238&filename=D0570C00007.pdf"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "The study has been performed in Sweden and Denmark at two University hospital clinics and two CROs. The recruitment period was between 11 August 2008 to 22 October 2008.", "groups": [{"id": "FG000", "title": "APCDEBa", "description": "AZD3199 120 Mcg followed by Placebo followed by AZD3199 1920 Mcg followed by Formoterol 9 Mcg followed by Formoterol 36 Mcg followed by AZD3199 480 Mcg."}, {"id": "FG001", "title": "BADEPCa", "description": "AZD3199 480 Mcg followed by AZD3199 120 Mcg followed by Formoterol 9 Mcg followed by Formoterol 36 Mcg followed by Placebo followed by AZD3199 1920 Mcg."}, {"id": "FG002", "title": "CBEPADa", "description": "AZD3199 1920 Mcg followed by AZD3199 480 Mcg followed by Formoterol 36 Mcg followed by Placebo followed by AZD3199 120 Mcg followed by Formoterol 9 Mcg ."}, {"id": "FG003", "title": "DCPABEa", "description": "Formoterol 9 Mcg followed by AZD3199 1920 Mcg followed by Placebo followed by AZD3199 120 Mcg followed by AZD3199 480 Mcg followed by Formoterol 36 Mcg."}, {"id": "FG004", "title": "EDABCPa", "description": "Formoterol 36 Mcg followed by Formoterol 9 Mcg followed by AZD3199 120 Mcg followed by AZD3199 480 Mcg followed by AZD3199 1920 Mcg followed by Placebo."}, {"id": "FG005", "title": "PEBCDAa", "description": "Placebo followed by Formoterol 36 Mcg followed by AZD3199 480 Mcg followed by AZD3199 1920 Mcg followed by Formoterol 9 Mcg followed by AZD3199 120 Mcg."}], "periods": [{"title": "Period 1", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "comment": "Cross-over study", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "6"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "1"}]}]}, {"title": "Period 2", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 3", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 4", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 5", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}, {"title": "Period 6", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "7"}, {"groupId": "FG004", "numSubjects": "7"}, {"groupId": "FG005", "numSubjects": "5"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}, {"groupId": "FG004", "numSubjects": "0"}, {"groupId": "FG005", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Baseline Total", "description": "Total number of patients randomized and treated in the study"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "37"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "FULL_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.3", "lowerLimit": "22", "upperLimit": "68"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "32"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "FEV1 Peak Effect Within 0 - 24 h Post-dose", "description": "Maximum FEV1 value", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.56", "spread": "0.94"}, {"groupId": "OG001", "value": "3.62", "spread": "0.94"}, {"groupId": "OG002", "value": "3.70", "spread": "1.02"}, {"groupId": "OG003", "value": "3.62", "spread": "1.01"}, {"groupId": "OG004", "value": "3.69", "spread": "0.97"}, {"groupId": "OG005", "value": "3.44", "spread": "0.99"}]}]}]}, {"type": "PRIMARY", "title": "E22-26: the Average of the FEV1 Value Between 22 and 26 h Post Dose for Every Treatment Visit.", "description": "Residual FEV1 24 h post-dose", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "22- 26 h post dose", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.31", "spread": "0.96"}, {"groupId": "OG001", "value": "3.35", "spread": "0.93"}, {"groupId": "OG002", "value": "3.40", "spread": "0.94"}, {"groupId": "OG003", "value": "3.26", "spread": "0.94"}, {"groupId": "OG004", "value": "3.36", "spread": "0.97"}, {"groupId": "OG005", "value": "3.23", "spread": "0.96"}]}]}]}, {"type": "PRIMARY", "title": "S-potassium, Peak Effect Over 0 - 4 h Post-dose", "description": "Minimum S-potassium concentration (A well-known effect of beta2-agonists (AZD3199 is a beta2-agonist) is a reduction in serum potassium levels. The minimum value has therefore been evaluated.", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "0, 15min, 30min,1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.04", "spread": "0.19"}, {"groupId": "OG001", "value": "4.03", "spread": "0.25"}, {"groupId": "OG002", "value": "3.98", "spread": "0.28"}, {"groupId": "OG003", "value": "4.04", "spread": "0.20"}, {"groupId": "OG004", "value": "3.84", "spread": "0.21"}, {"groupId": "OG005", "value": "4.04", "spread": "0.23"}]}]}]}, {"type": "PRIMARY", "title": "S-potassium, Average Effect Over 0 - 4 h Post-dose", "description": "Average S-potassium concentration", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on AZD3199 1920 mcg had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmol/L", "timeFrame": "0, 15min, 30min,1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "33"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "4.22", "spread": "0.19"}, {"groupId": "OG001", "value": "4.21", "spread": "0.26"}, {"groupId": "OG002", "value": "4.17", "spread": "0.26"}, {"groupId": "OG003", "value": "4.19", "spread": "0.20"}, {"groupId": "OG004", "value": "3.99", "spread": "0.17"}, {"groupId": "OG005", "value": "4.21", "spread": "0.25"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 Effect at 5 Min Post-dose", "description": "FEV1 at 5 minutes", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. Two patients on Placebo and 1 on AZD3199 480 mcg had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "5min", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "33"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.36", "spread": "0.88"}, {"groupId": "OG001", "value": "3.38", "spread": "0.92"}, {"groupId": "OG002", "value": "3.33", "spread": "1.03"}, {"groupId": "OG003", "value": "3.37", "spread": "0.95"}, {"groupId": "OG004", "value": "3.47", "spread": "0.93"}, {"groupId": "OG005", "value": "3.13", "spread": "0.86"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 Average Effect Over 0 - 24 h Post-dose", "description": "FEV1 average effect over 24 h dosing interval", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h, 18h, 22h, 24h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.31", "spread": "0.93"}, {"groupId": "OG001", "value": "3.36", "spread": "0.91"}, {"groupId": "OG002", "value": "3.44", "spread": "0.95"}, {"groupId": "OG003", "value": "3.35", "spread": "0.98"}, {"groupId": "OG004", "value": "3.46", "spread": "0.96"}, {"groupId": "OG005", "value": "3.19", "spread": "0.95"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 Average Effect Over 0 - 12 h Post-dose", "description": "FEV1 average effect over 12 h day-time period", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.33", "spread": "0.92"}, {"groupId": "OG001", "value": "3.40", "spread": "0.89"}, {"groupId": "OG002", "value": "3.48", "spread": "0.97"}, {"groupId": "OG003", "value": "3.40", "spread": "0.98"}, {"groupId": "OG004", "value": "3.51", "spread": "0.95"}, {"groupId": "OG005", "value": "3.20", "spread": "0.96"}]}]}]}, {"type": "SECONDARY", "title": "FEV1 Average Effect Over 12 - 24 h Post-dose", "description": "FEV1 average effect over 12 h night-time period", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo treatment had data not sufficient for computing PD parameters and for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "L", "timeFrame": "12h, 14h, 18h, 22h, 24h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.28", "spread": "0.95"}, {"groupId": "OG001", "value": "3.33", "spread": "0.92"}, {"groupId": "OG002", "value": "3.41", "spread": "0.94"}, {"groupId": "OG003", "value": "3.30", "spread": "0.98"}, {"groupId": "OG004", "value": "3.40", "spread": "0.98"}, {"groupId": "OG005", "value": "3.19", "spread": "0.95"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum SBP value over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "126.8", "spread": "14.5"}, {"groupId": "OG001", "value": "128.3", "spread": "13.4"}, {"groupId": "OG002", "value": "127.4", "spread": "12.0"}, {"groupId": "OG003", "value": "127.3", "spread": "13.2"}, {"groupId": "OG004", "value": "129.9", "spread": "12.1"}, {"groupId": "OG005", "value": "126.4", "spread": "14.4"}]}]}]}, {"type": "SECONDARY", "title": "Systolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose", "description": "Average SBP value over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "121.1", "spread": "13.7"}, {"groupId": "OG001", "value": "121.8", "spread": "11.8"}, {"groupId": "OG002", "value": "121.3", "spread": "11.9"}, {"groupId": "OG003", "value": "120.9", "spread": "12.8"}, {"groupId": "OG004", "value": "122.6", "spread": "11.8"}, {"groupId": "OG005", "value": "121.3", "spread": "13.5"}]}]}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure, Peak Effect Over 0 - 4 h Post-dose", "description": "Minimum DBP value over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "67.3", "spread": "10.3"}, {"groupId": "OG001", "value": "67.6", "spread": "7.9"}, {"groupId": "OG002", "value": "66.7", "spread": "9.6"}, {"groupId": "OG003", "value": "66.9", "spread": "9.1"}, {"groupId": "OG004", "value": "66.7", "spread": "9.6"}, {"groupId": "OG005", "value": "68.8", "spread": "8.0"}]}]}]}, {"type": "SECONDARY", "title": "Diastolic Blood Pressure, Average Effect Over 0 - 4 h Post-dose", "description": "Average DBP value over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "71.4", "spread": "10.0"}, {"groupId": "OG001", "value": "72.0", "spread": "8.9"}, {"groupId": "OG002", "value": "71.6", "spread": "9.5"}, {"groupId": "OG003", "value": "71.5", "spread": "9.2"}, {"groupId": "OG004", "value": "71.0", "spread": "8.6"}, {"groupId": "OG005", "value": "72.7", "spread": "8.4"}]}]}]}, {"type": "SECONDARY", "title": "Pulse, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum pulse over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "62.1", "spread": "9.4"}, {"groupId": "OG001", "value": "65.0", "spread": "11.0"}, {"groupId": "OG002", "value": "66.7", "spread": "9.9"}, {"groupId": "OG003", "value": "63.6", "spread": "11.0"}, {"groupId": "OG004", "value": "67.3", "spread": "11.6"}, {"groupId": "OG005", "value": "65.3", "spread": "10.4"}]}]}]}, {"type": "SECONDARY", "title": "Pulse, Average Effect Over 0 - 4 h Post-dose", "description": "Average pulse over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "57.1", "spread": "8.0"}, {"groupId": "OG001", "value": "59.0", "spread": "8.7"}, {"groupId": "OG002", "value": "61.9", "spread": "9.1"}, {"groupId": "OG003", "value": "58.6", "spread": "9.4"}, {"groupId": "OG004", "value": "62.8", "spread": "10.1"}, {"groupId": "OG005", "value": "58.8", "spread": "8.8"}]}]}]}, {"type": "SECONDARY", "title": "Heart Rate, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum heart rate over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "64.0", "spread": "8.8"}, {"groupId": "OG001", "value": "64.1", "spread": "9.6"}, {"groupId": "OG002", "value": "66.9", "spread": "9.5"}, {"groupId": "OG003", "value": "63.8", "spread": "10.2"}, {"groupId": "OG004", "value": "66.8", "spread": "10.9"}, {"groupId": "OG005", "value": "64.5", "spread": "11.3"}]}]}]}, {"type": "SECONDARY", "title": "Heart Rate, Average Effect Over 0 - 4 h Post-dose", "description": "Average heart rate over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "bpm", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "58.3", "spread": "7.9"}, {"groupId": "OG001", "value": "59.0", "spread": "8.5"}, {"groupId": "OG002", "value": "61.8", "spread": "9.0"}, {"groupId": "OG003", "value": "58.6", "spread": "9.2"}, {"groupId": "OG004", "value": "62.7", "spread": "10.0"}, {"groupId": "OG005", "value": "58.1", "spread": "8.6"}]}]}]}, {"type": "SECONDARY", "title": "QTcB, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum QTc Bazett over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ms", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "412", "spread": "21.6"}, {"groupId": "OG001", "value": "407", "spread": "22.8"}, {"groupId": "OG002", "value": "413", "spread": "22.0"}, {"groupId": "OG003", "value": "408", "spread": "21.6"}, {"groupId": "OG004", "value": "415", "spread": "24.6"}, {"groupId": "OG005", "value": "408", "spread": "20.8"}]}]}]}, {"type": "SECONDARY", "title": "QTcB, Average Effect Over 0 - 4 h Post-dose", "description": "Average QTc Bazett over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ms", "timeFrame": "0, 30min, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "35"}, {"groupId": "OG005", "value": "35"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "398", "spread": "19.9"}, {"groupId": "OG001", "value": "397", "spread": "22.3"}, {"groupId": "OG002", "value": "402", "spread": "21.2"}, {"groupId": "OG003", "value": "395", "spread": "21.4"}, {"groupId": "OG004", "value": "406", "spread": "24.4"}, {"groupId": "OG005", "value": "395", "spread": "19.8"}]}]}]}, {"type": "SECONDARY", "title": "Tremor, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "34"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.06", "spread": "0.24"}, {"groupId": "OG001", "value": "0.06", "spread": "0.24"}, {"groupId": "OG002", "value": "0.17", "spread": "0.45"}, {"groupId": "OG003", "value": "0.11", "spread": "0.32"}, {"groupId": "OG004", "value": "0.47", "spread": "0.66"}, {"groupId": "OG005", "value": "0.03", "spread": "0.17"}]}]}]}, {"type": "SECONDARY", "title": "Tremor, Average Effect Over 0 - 4 h Post-dose", "description": "Average tremor score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h.", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "34"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.02"}, {"groupId": "OG001", "value": "0.02", "spread": "0.08"}, {"groupId": "OG002", "value": "0.04", "spread": "0.11"}, {"groupId": "OG003", "value": "0.05", "spread": "0.18"}, {"groupId": "OG004", "value": "0.16", "spread": "0.34"}, {"groupId": "OG005", "value": "0.01", "spread": "0.06"}]}]}]}, {"type": "SECONDARY", "title": "Palpitations, Peak Effect Over 0 - 4 h Post-dose", "description": "Maximum palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "34"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.03", "spread": "0.17"}, {"groupId": "OG001", "value": "0.03", "spread": "0.17"}, {"groupId": "OG002", "value": "0.09", "spread": "0.37"}, {"groupId": "OG003", "value": "0.00", "spread": "0.00"}, {"groupId": "OG004", "value": "0.18", "spread": "0.52"}, {"groupId": "OG005", "value": "0.00", "spread": "0.00"}]}]}]}, {"type": "SECONDARY", "title": "Palpitations, Average Effect Over 0 - 4 h Post-dose", "description": "Average palpitation score (4 grade scale: 0=no, 1=mild, 2=moderate or 3=severe) over 4 h", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacodynamic analysis set since these patients are non-informative regarding treatment differences. One patient on Placebo, 1 patient on formoterol 36 mcg and 1 patient on AZD3199 480 mcg had no data for subsequent analysis.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale", "timeFrame": "0, 15min, 30min, 1h, 2h, 4h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "34"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "35"}, {"groupId": "OG004", "value": "34"}, {"groupId": "OG005", "value": "34"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.00", "spread": "0.02"}, {"groupId": "OG001", "value": "0.01", "spread": "0.05"}, {"groupId": "OG002", "value": "0.02", "spread": "0.08"}, {"groupId": "OG003", "value": "0.00", "spread": "0.00"}, {"groupId": "OG004", "value": "0.11", "spread": "0.33"}, {"groupId": "OG005", "value": "0.00", "spread": "0.00"}]}]}]}, {"type": "SECONDARY", "title": "Plasma AZD3199 Cmax", "description": "Maximum plasma concentration of AZD3199 measured", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "nmol/L", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.99", "lowerLimit": "0.21", "upperLimit": "2.83"}, {"groupId": "OG001", "value": "5.39", "lowerLimit": "1.32", "upperLimit": "12.4"}, {"groupId": "OG002", "value": "24.55", "lowerLimit": "8.99", "upperLimit": "44.3"}]}]}]}, {"type": "SECONDARY", "title": "Plasma AZD3199 AUC0-24", "description": "Area under the plasma concentration curve from time 0 to 24 h post-dose", "populationDescription": "Two patients discontinued after the first treatment period and were excluded from pharmacokinetic analysis set.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Full Range", "unitOfMeasure": "nmol*h/L", "timeFrame": "0, 5min, 15min, 30min, 1h, 2h, 4h, 8h, 12h, 24h", "groups": [{"id": "OG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler"}, {"id": "OG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler"}, {"id": "OG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler"}, {"id": "OG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler"}, {"id": "OG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler"}, {"id": "OG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "35"}, {"groupId": "OG002", "value": "35"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.83", "lowerLimit": "0.3", "upperLimit": "5.2"}, {"groupId": "OG001", "value": "9.75", "lowerLimit": "2.9", "upperLimit": "23.5"}, {"groupId": "OG002", "value": "46.06", "lowerLimit": "14.6", "upperLimit": "106.2"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "AZD3199 120 mcg", "description": "AZD3199 120 Mcg inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 4, "otherNumAtRisk": 36}, {"id": "EG001", "title": "AZD3199 480 mcg", "description": "AZD3199 480 Mcg inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 3, "otherNumAtRisk": 35}, {"id": "EG002", "title": "AZD3199 1920 mcg", "description": "AZD3199 1920 Mcg inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 10, "otherNumAtRisk": 35}, {"id": "EG003", "title": "Formoterol 9 mcg", "description": "Formoterol 9 Mcg inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 2, "otherNumAtRisk": 35}, {"id": "EG004", "title": "Formoterol 36 mcg", "description": "Formoterol 36 Mcg inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 35, "otherNumAffected": 4, "otherNumAtRisk": 35}, {"id": "EG005", "title": "Placebo", "description": "Placebo inhaled via Turbuhaler", "seriousNumAffected": 0, "seriousNumAtRisk": 36, "otherNumAffected": 6, "otherNumAtRisk": 36}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 10.0", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 35}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 35}, {"groupId": "EG004", "numAffected": 3, "numAtRisk": 35}, {"groupId": "EG005", "numAffected": 2, "numAtRisk": 36}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 10.0", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 35}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG004", "numAffected": 1, "numAtRisk": 35}, {"groupId": "EG005", "numAffected": 4, "numAtRisk": 36}]}, {"term": "Throat irritation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 10.0", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 36}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 35}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 35}, {"groupId": "EG005", "numAffected": 0, "numAtRisk": 36}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Prior to any publication or disclosure, the PI provides AstraZeneca with preliminary data and drafts and with the proposed final manuscript. AstraZeneca shall have a period of 30 days from receipt of the proposed final manuscript to review it and may within such time frame require that submission for publication or disclosure be delayed."}, "pointOfContact": {"title": "Carin Jorup, MSD", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Finland"]}, "conditionBrowseModule": {"meshes": [{"id": "D000000402", "term": "Airway Obstruction"}], "ancestors": [{"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000012131", "term": "Respiratory Insufficiency"}, {"id": "D000012120", "term": "Respiration Disorders"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "M3750", "name": "Airway Obstruction", "asFound": "Airway Obstruction", "relevance": "HIGH"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M14968", "name": "Respiratory Insufficiency", "relevance": "LOW"}, {"id": "M14957", "name": "Respiration Disorders", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "C000544523", "term": "AZD-3199"}], "ancestors": [{"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M304", "name": "Formoterol Fumarate", "asFound": "Nicotine", "relevance": "HIGH"}, {"id": "M224548", "name": "AZD-3199", "asFound": "Nutritional advice", "relevance": "HIGH"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}